Skip to main content

Advertisement

SpringerLink
Log in

Polatuzumab Vedotin: a New Target for B Cell Malignancies

  • T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Antibody-drug conjugates are a new class of therapeutic agents in the treatment of B cell malignancies. In this review, we summarize the recent developments of polatuzumab vedotin in the treatment of relapsed or refractory diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL).

Recent Findings

Polatuzumab vedotin recently received its first FDA approval in combination with bendamustine and rituximab for the treatment of patients with relapsed or refractory DLBCL. Polatuzumab vedotin has been evaluated and is being studied in combinations with chemoimmunotherapy, immunomodulating agents, bispecific antibodies, and venetoclax. These studies have shown promising results in early phase trials.

Summary

While further studies in a larger patient population are needed in order to determine an optimal combination regimen for polatuzumab vedotin, the ongoing trials represent a growing list of potential therapeutic options for the patients with relapsed or refractory NHL and newly diagnosed NHL alike.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Yu B, Liu D. Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. J Hematol Oncol. 2019;12:94.

    Article  Google Scholar 

  2. D'Arena G, Musto P, Cascavilla N, Dell'Olio M, Di Renzo N, Carotenuto M. Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. Am J Hematol. 2000;64:275–81.

    Article  Google Scholar 

  3. Young RM, Shaffer AL 3rd, Phelan JD, Staudt LM. B-cell receptor signaling in diffuse large B-cell lymphoma. Semin Hematol. 2015;52:77–85.

    Article  CAS  Google Scholar 

  4. The Human Protein Atlas. CD79B. 2019, at https://www.proteinatlas.org/ENSG00000007312-CD79B/pathology.)

  5. Polivy™ (Polatuzumab vedotin-piiq) for injection, for intravenous use: Highlights of Prescribing Information. 2019.

  6. Palanca-Wessels MCA, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, et al. Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16:704–15.

    Article  CAS  Google Scholar 

  7. Hatake K, Kinoshita T, Terui Y, et al. A phase I pharmacokinetic and safety study of polatuzumab vedotin in Japanese patients with relapsed/refractory b-cell non-Hodgkin lymphoma: A comparison with non-Japanese DCS4968g study. J Clin Oncol. 2016;34:e19070–e.

    Article  Google Scholar 

  8. • Morschhauser F, Flinn IW, Advani R, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019;6:e254–e65 The ROMULUS trial was the first phase II trial to evaluate the combination of pola with a CD20 monoclonal antibody. With the ORR of 54% and 21% CR rate in the DLBCL population, this trial solidified the pola's role as a viable therapeutic agent in the treatment of R/R DLBCL.

    Article  Google Scholar 

  9. Tobinai K, Klein C, Oya N, Fingerle-Rowson G. A review of Obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies. Adv Ther. 2017;34:324–56.

    Article  CAS  Google Scholar 

  10. Phillips T, Brunvand M, Chen A, et al. Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study. Blood. 2016;128:622.

    Article  Google Scholar 

  11. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2019:JCO.19.00172.

  12. •• Sehn LH, Matasar MJ, Flowers CR, et al. Polatuzumab Vedotin plus Bendamustine with rituximab in relapsed/refractory diffuse large B-cell lymphoma: updated results of a phase Ib/II randomized study. Blood. 2019;134:4081 The randomized phase II trial of this study led to the first FDA approval for pola in combination with bendamustine and rituximab for the treatment of patients with R/R DLBCL who have received at least two prior lines of thearpy.

    Article  Google Scholar 

  13. Sehn LH, Herrera AF, Matasar MJ, et al. Addition of Polatuzumab Vedotin to Bendamustine and Rituximab (BR) Improves Outcomes in Transplant-Ineligible Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Versus BR Alone: Results from a Randomized Phase 2 Study. Blood. 2017;130:2821.

    Google Scholar 

  14. FDA approves polatuzumab vedotin-piiq for diffuse large B-cell lymphoma. 2019. at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-polatuzumab-vedotin-piiq-diffuse-large-b-cell-lymphoma.

  15. Tilly H, Morschhauser F, Bartlett NL, Mehta A, Salles G, Haioun C, et al. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study. Lancet Oncol. 2019;20:998–1010.

    Article  CAS  Google Scholar 

  16. • Tilly H, Flowers C, Friedberg JW, et al. POLARIX: a phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL. J Clin Oncol. 2019;37:TPS7571–TPS The POLARIX trial is the first phase III trial of pola in combiation with chemoimmunotherapy in newly diagnosed DLBCL patientsResults of the POLARIX study are eagerly awaited.

    Article  Google Scholar 

  17. Forero-Torres A, Kolibaba KS, Lamy T, Jones S, Lee C, Sharman J. Polatuzumab Vedotin Combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study. Blood. 2016;128:1856.

    Article  Google Scholar 

  18. Morschhauser F, Le Gouill S, Feugier P, et al. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. Lancet Haematol. 2019;6:e429–e37.

    Article  Google Scholar 

  19. Gribben JG, Fowler N, Morschhauser F. Mechanisms of action of Lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol. 2015;33:2803–11.

    Article  CAS  Google Scholar 

  20. • Catherine Diefenbach M, Brad S. Kahl M, Lalita Banerjee F, et al. Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population in a Phase Ib/II Trial. American Society of Hematology Annual Meeting 2019;Abstract 126. This is the first trial to study a novel triplet combination with pola, anti-CD20 antibody and an immunomodulating agent in R/R FL, with promising results of tolerability and antitumor activity in the primary analysis of the full efficacy population reported in an abstract format at the 2019 American Society of Hematology annual conference.

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Medical Oncology, Perlmutter Cancer Center at NYU Langone Health, New York University School of Medicine & Langone Medical Center, 240 East 38th Street, 19th Floor, New York, NY, 10016, USA

    Yun Choi & Catherine S. Diefenbach

Authors
  1. Yun Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Catherine S. Diefenbach
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Catherine S. Diefenbach.

Ethics declarations

Conflict of Interest

CD: Consulting and research funding: Roche/Genentech. The authors declare no other conflict of interest that is relevant to this review article

Human and Animal Rights and Informed Consent

CD participated in one of the studies referenced in the article.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on T-Cell and Other Lymphoproliferative Malignancies

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Choi, Y., Diefenbach, C.S. Polatuzumab Vedotin: a New Target for B Cell Malignancies. Curr Hematol Malig Rep 15, 125–129 (2020). https://doi.org/10.1007/s11899-020-00572-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-020-00572-7

Keywords

Search

Navigation